Program
tilrekimig
Also written as “PF-07275315”, “Tilrekimig” and “PF-07275315 dose 1”.
In Pfizer's pipeline, anti-IL-4/ IL-13/ TSLP
. Its studies are mostly in Dermatitis, Atopic · Asthma · Pulmonary Disease, Chronic Obstructive, led by Pfizer.
Furthest: phase 3, since Jan 22, 202611 company-led studies, 9 open or runningNext primary completion: Feb 20, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 119 open or running | phase 3since Jan 22, 2026 | Jun 6, 2022 | Feb 20, 2027phase 1 · NCT07792941 |
- Named in Pfizer’s own pipeline as
tilrekimig PF-07275315
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05411588 · 65 enrolled · United States, Belgium
- Jul 26, 2023Phase 2 study in Dermatitis, AtopicNCT05995964 · 507 enrolled · United States, Australia, Canada and more
- Nov 4, 2024Phase 1 study in HealthyNCT06675188 · 13 enrolled · China
- Apr 25, 2025Phase 2 study in AsthmaNCT06977581 · 252 planned · United States, Argentina, Belgium and more
- Jan 22, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07363694 · 1,156 planned · United States, Argentina, Australia and more
- Aug 10, 20263 phase 3 studiesNCT07765888, NCT07772921, NCT07783425
- Aug 25, 2026Phase 1 study in HealthyNCT07792941 · 12 enrolled · United States
- Sep 18, 20262 phase 3 studiesNCT07839884, NCT07869043
Ahead
- Nov 12, 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT05995964
- Feb 20, 2027Primary completion: phase 1 study in HealthyNCT07792941
- Mar 8, 2027Primary completion: phase 2 study in AsthmaNCT06977581
- Mar 10, 2028Primary completion: phase 3 study in Dermatitis, AtopicNCT07765888
TargetBeta
“anti-IL-4/ IL-13/ TSLP”the company's pipeline, read by Claude · source
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07869043Asthma · United States, Puerto Rico | 3 | Recruiting | Jun 7, 2029 | 1,100 |
| NCT07839884Pulmonary Disease, Chronic Obstructive | 3 | Not yet recruiting | May 12, 2034 | 1,360 |
| NCT07792941Healthy · United States | 1 | Active, not recruiting | Feb 20, 2027 | 12 |
| NCT07783425Dermatitis, Atopic · United States, Canada, Japan and more | 3 | Recruiting | Sep 8, 2028 | 1,375 |
| NCT07772921Asthma · United States, Japan | 3 | Recruiting | Jun 1, 2029 | 1,100 |
| NCT07765888Dermatitis, Atopic · United States, Canada, Japan | 3 | Recruiting | Mar 10, 2028 | 375 |
| NCT07363694Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | Oct 24, 2030 | 1,156 |
| NCT06977581Asthma · United States, Argentina, Belgium and more | 2 | Recruiting | Mar 8, 2027 | 252 |
| NCT06675188Healthy · China | 1 | Completed | Jul 14, 2025 | 13 |
| NCT05995964Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Active, not recruiting | Nov 12, 2026 | 507 |
| NCT05411588Healthy Volunteers · United States, Belgium | 1 | Completed | May 13, 2024 | 65 |
How it is read
Names in the registry
- “PF-07275315”, 4 entries
- “Tilrekimig”, 3 entries
- “tilrekimig”, 2 entries
- “PF-07275315 dose 1”, 1 entry
- “PF-07275315-dose 2”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Asthma, 3 studies
- Pulmonary Disease, Chronic Obstructive, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.